|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:clinicalTrialsGovURL
|
https://clinicaltrials.gov/ct2/show/NCT01314313
|
|
gptkbp:compared
|
TAVR vs surgical aortic valve replacement
|
|
gptkbp:deviceStudied
|
SAPIEN 3 valve
SAPIEN XT valve
|
|
gptkbp:enrollmentEndYear
|
2013
|
|
gptkbp:enrollmentStartYear
|
2011
|
|
gptkbp:foundIn
|
TAVR was noninferior to surgery for the primary endpoint in intermediate-risk patients
|
|
gptkbp:fullName
|
Placement of Aortic Transcatheter Valves II trial
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PARTNER II trial
|
|
gptkbp:location
|
gptkb:Canada
gptkb:Europe
gptkb:United_States
|
|
gptkbp:number
|
NCT01314313
|
|
gptkbp:participants
|
2032
|
|
gptkbp:period
|
Phase 3
|
|
gptkbp:population
|
intermediate-risk patients with severe aortic stenosis
|
|
gptkbp:principalInvestigator
|
gptkb:Craig_R._Smith
gptkb:Martin_B._Leon
|
|
gptkbp:publicationYear
|
2016
|
|
gptkbp:publishedIn
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:result
|
death or disabling stroke at 2 years
|
|
gptkbp:sponsor
|
gptkb:Edwards_Lifesciences
|
|
gptkbp:studiedBy
|
severe aortic stenosis
transcatheter aortic valve replacement
|
|
gptkbp:bfsParent
|
gptkb:SAPIEN_XT
|
|
gptkbp:bfsLayer
|
8
|